Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A/S INCREASE OR R/S.HE HAS NO CHOICE.ALSO 40 MILLION SHARES CAME OFF RESTRICTION.THEY WILL BE LOOKING TO SELL.
THEY WILL NEED A TON OF VOLUMES TO SELL.
Fdc4 Go back read your last post 0 sense.
Fdc4 What is your highest level of education?
What do you mean Slop? You have babbling and talking sooo many non-stop $HIT!!! That people don’t know what you said or didn’t say anymore. I think you said it all and you were into every conversation too. Yes you said it
Hahahahahahaha, darn. Finally, well put
Nope. He will need attorney letter and a small white lie
Do yourself a favor and stop talking...what on earth are you babbling.....
They are never good
I have been in only 1 R/S that was good for s/h
Exactly. I think the muthafucker is getting current so he can RS this again!
Fasctrack Please notice I never said at this time
Slops I appreciate your optimism however, IMHO a buy-back scenario with this company seems next to impossible and completely unrealistic at this point. Per the statement of Cash Flows, cash from operations increased by a whopping $175!!! With over a billion shares outstanding, the company doesn't just need a few good contracts, the company needs some huge contracts of material dollar amounts billed AND COLLECTED over a sustained period of time to even consider such a scenario. I suppose it could happen...kind of like the odds of winning the Powerball or getting struck by lightening. Still holding.
Would be nice to get a little news this week
Your spelling not mine>>> job and fillng......late. LOL
You're dam* right I'm glad im not you....I'd be very embarrassed at this point 😂 😢
Glad U agree a few contracts Lot's of cash
Probably top 5 dumbest posts ever showing complete lack of knowledge......need lots of cash for that 😂 😂 😂
As I was saying....😂 😂 😢
He will at some point ☺ Company will eventually have to raise the AS and sell more shares ☺
Makes ZERO sense...what else would they take? Ious? They have no $$$
I know right.....funny to watch this shi* show board daily....especially the board's ignorant 🤡
Surely one of the dumbest I've ever run across 😂 😢
how long does it take for that effing yield sign to come down? and my prediction, based on nothing, is news next week. so get your popcorn ready cuz the shizzle gonna hit the fan
Really??? From doing their job and fillng......late.
😂 😂 😂 😢 😢
THE FILINGS DID NOT DO CRAP.OTIKO PLAYED THE GAME TO SHAKE TRADERS OUT.BY NOT FILING ON TIME.THE DIRT BAG.ALWAYS ON PURPOSE.
Could be that you scared everyone off?
I agree but appears no price movement on it.
guess you never got a chance to buy your .007s don't be mad at us but i am sure if and when we have a run $$$ you will say you have 5 million shares ... same old story
LMAO.AND THE STOCK SAYS??????ZERO INTEREST.SO ALL THAT NOISE FOR THE FILINGS DID WHAT???LMAOO
Seems logical to me The return will be more
What I found very interesting is that a whole lot of people and holders of debt or judgements have taken common stock as payment. Seems there is faith in the company's future.
Such crap! What happened to the "major" shipment of product overseas happening in March? All bullshit, like most all the gibberish on this board. Big news my ass. Credibility? VDRM lost that a long time ago. GFAOY!
so much for the EXPERTS🤡 on EXPERT 🙂
now that the annual is filed let's get this show on the road with some BIG news releases!!!
Probably will see a “PUFF” piece PR claiming about some multi-million dollar PO from overseas…..
Anyone here think annual has enough to get another bump here.???
Report Hopefully this week, no one want to sell, sitting tight.
If you are still out of the mental facility Slop, I will be darned if I need any help
I think UR LOSING it MATE try getting help
Where have you been mate? Did you get a brain wash or something. That has been clear since the first license states were given. I don’t know why you are bringing that now. Check previous filings
Before it was published, you fool. Check the old posts. Chuckles
Followers
|
619
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
74597
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |